The Cancer SIGNAL GRAIL

Jon Rendina and Dwight Venson of Whitman-Walker, a healthcare center historically focused on the LGBTQ+ community, join us to delve into how LGBTQ+ people and people of color face disparities in cancer incidence. Whitman-Walker, Cancer Support Community, and GRAIL are collaborating on INCLUDE, a study to evaluate multi-cancer early detection (MCED) testing’s impact within federally qualified health centers. The goal: make this kind of cancer screening available to more people in the future. Jon and Dwight discuss barriers to access, how LGTBQ+ and minority experiences of cancer care can be different, and how MCED testing may play a role in helping underserved groups.
 
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 
Transcripts: https://grail.com/podcast/ 
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Diverse clinical trials provide more meaningful data to researchers, but too many trials are based around monolithic audience groups. In early disease detection, particularly in conditions like cancer, diversity in clinical trials is especially important. Our guests, Eucharia Borden of the cancer nonprofit Family Reach and Dr. Gary Puckrein of the National Minority Quality Forum, discuss why diversity in clinical trials is critical and how to foster inclusivity in clinical research, getting us closer to healthcare equity. 
Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 
Transcripts: https://grail.com/podcast/ 
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

After supporting her husband through his shocking cancer experience, Cindy decided to take a multi-cancer early detection test as recommended by her doctor. She was once again shocked when she received a “cancer signal detected” result, leading to a cancer diagnosis. Join us to hear about Cindy’s experience with early detection, treatment, and eventual remission, and what she learned along the way.
We want your feedback! Please take our podcast survey: https://bit.ly/42R4wGi 
Transcripts: https://grail.com/podcast/ 
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Join host Kim Thiboldeaux and Krissa Smith, VP of Mission Partnerships at Susan G. Komen, as they continue unraveling how the BRCA gene and other DNA mutations impact hereditary cancer risk. In this episode, Krissa shares personal stories about her family's experiences with genetic testing and how they’ve chosen to respond. Krissa also discusses cancer screening best practices and how multi-cancer early detection testing can play a role.
Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN  
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Krissa Smith, Vice President of Mission Partnerships at Susan G. Komen, joins us to discuss the complexities of the BRCA gene and its impact on hereditary cancer risk. Krissa shares her family's experiences with genetic mutations, including the p53 gene, and explains the importance of genetic testing and how it can work in partnership with evolving cancer screening technology. Stay tuned for part 2 to learn more about genetics, cancer risk, and the importance of early detection.
Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN  
Transcripts: https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Meet Tami, manager of a Christmas tree farm in rural Oregon. Cancer has had a profound impact on Tami’s life, from her grandmother's diagnosis more than 30 years ago to her own 2017 diagnosis to her participation in the PATHFINDER study. Tami shares what she’s learned about cancer and the importance of proactive screening, including her own experiences with multi-cancer early detection (MCED) testing. 
Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN 
Transcripts: https://grail.com/podcast/ 
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/